Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes

• Published in: Clinical journal of the American Society of Nephrology 2019-06, Vol.14 (6), p.862-872
• Main Authors: Ohkuma, Toshiaki, Jun, Min, Chalmers, John, Cooper, Mark E, Hamet, Pavel, Harrap, Stephen, Zoungas, Sophia, Perkovic, Vlado, Woodward, Mark
• Format: Article
• Language: English
• Subjects: Aged; Albuminuria - urine; Cardiovascular Diseases - mortality; Creatinine - urine; Diabetes Mellitus, Type 2 - physiopathology; Diabetic Nephropathies - epidemiology; Diabetic Nephropathies - therapy; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Mortality; Myocardial Infarction - epidemiology; Original; Randomized Controlled Trials as Topic; Renal Replacement Therapy - statistics & numerical data; Risk Factors; Stroke - epidemiology
• ISSN: 1555-9041; 1555-905X; 1555-905X
• DOI: 10.2215/CJN.13391118

Whether combining changes in eGFR and urine albumin-to-creatinine ratio (UACR) is more strongly associated with outcomes compared with either change alone is unknown. We analyzed 8766 patients with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation Observational (ADVANCE-ON) study. Changes in eGFR and UACR (baseline to 2 years) were defined as ≥40% decrease, minor change, and ≥40% increase. The primary outcome was the composite of major macrovascular (nonfatal or fatal myocardial infarction, nonfatal or fatal stroke, or cardiovascular death), major kidney events (requirement for kidney replacement therapy or kidney death), and all-cause mortality. Over a median of 7.7 years of follow-up, 2191 primary outcomes were recorded. Strong linear associations between eGFR and UACR changes and subsequent risk of the outcome were observed. For eGFR, the hazard ratios were 1.58 (95% confidence interval [95% CI], 1.27 to 1.95) for a decrease ≥40% and 0.82 for an increase ≥40% (95% CI, 0.64 to 1.04) compared with minor change. For UACR, the hazard ratios were 0.96 (95% CI, 0.85 to 1.07) for a decrease ≥40% and 1.32 (95% CI, 1.19 to 1.46) for ≥40% increase compared with minor change. Compared with dual minor changes, both an eGFR decrease ≥40% and a UACR increase ≥40% had 2.31 (95% CI, 1.67 to 3.18) times the risk of the outcome, with evidence of interaction between the two markers. Clinically meaningful decreases in eGFR and increases in UACR over 2 years, independently and in combination, were significantly associated with higher risk of major clinical outcomes.